$99.51 +1.82 (%) Biomarin Pharmaceutical Inc - NASDAQ

Jan. 26, 2015 | 04:00 PM

Partner Headlines

  1. BIOMARIN PHARMA

    IBD | Jan. 21, 2015 | 18:42PM EST
  2. State Of The Union Lights Up Biotech

    Benzinga | Jan. 21, 2015 | 06:25AM EST
  3. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga | Jan. 16, 2015 | 15:34PM EST
  4. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data

    Benzinga | Jan. 14, 2015 | 07:08AM EST
  5. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  6. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD | Jan. 9, 2015 | 15:42PM EST
  7. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD | Jan. 8, 2015 | 08:02AM EST
  8. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale

    Benzinga | Jan. 6, 2015 | 12:34PM EST
  9. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD | Dec. 23, 2014 | 16:11PM EST
  10. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside

    Benzinga | Dec. 11, 2014 | 10:04AM EST
  11. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

    Benzinga | Dec. 10, 2014 | 08:05AM EST
  12. BioMarin Will Report Breadth of Innovative Development Pipeline at Analyst, Investor Day

    Benzinga | Dec. 9, 2014 | 08:05AM EST
  13. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga | Nov. 24, 2014 | 20:20PM EST
  14. BioMarin buying Prosensa

    IBD | Nov. 24, 2014 | 18:43PM EST
  15. Trio Of Major Deals Disclosed

    IBD | Nov. 24, 2014 | 18:42PM EST
  16. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetraphase Pharmaceuticals Shares Spike Higher

    Benzinga | Nov. 24, 2014 | 15:26PM EST
  17. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News

    Benzinga | Nov. 24, 2014 | 13:55PM EST
  18. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For $17.75/Share

    Benzinga | Nov. 24, 2014 | 11:54AM EST
  19. Benzinga's Volume Movers

    Benzinga | Nov. 24, 2014 | 10:28AM EST
  20. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD | Nov. 24, 2014 | 10:22AM EST
  21. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 24, 2014 | 10:18AM EST
  22. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  23. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD | Nov. 24, 2014 | 09:19AM EST
  24. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga | Nov. 24, 2014 | 09:06AM EST
  25. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 24, 2014 | 08:10AM EST
  26. US Stock Futures Up Ahead Of Economic Data

    Benzinga | Nov. 24, 2014 | 07:20AM EST
  27. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 10, 2014 | 10:17AM EST
  28. Benzinga's Top Upgrades

    Benzinga | Nov. 10, 2014 | 09:17AM EST
  29. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga | Oct. 21, 2014 | 20:11PM EST
  30. BioMarin Weathers The Storm

    Benzinga | Aug. 6, 2014 | 16:02PM EST
  31. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD | Aug. 5, 2014 | 18:30PM EST
  32. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD | Jun. 30, 2014 | 17:00PM EST
  33. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga | Jun. 9, 2014 | 09:41AM EST
  34. Benzinga's Top Upgrades

    Benzinga | Jun. 9, 2014 | 07:52AM EST
  35. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Mar. 12, 2014 | 10:01AM EST
  36. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

    Benzinga | Feb. 27, 2014 | 12:26PM EST
  37. Top Trending Tickers On StockTwits For February 18

    Benzinga | Feb. 18, 2014 | 10:22AM EST
  38. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  39. You Can No Longer Ignore Biotech

    GuruFocus | Feb. 7, 2014 | 17:32PM EST
  40. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga | Jan. 29, 2014 | 11:44AM EST
  41. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)

    Benzinga | Jan. 11, 2014 | 11:46AM EST
  42. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns

    Benzinga | Nov. 27, 2013 | 11:10AM EST
  43. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook

    Benzinga | Nov. 27, 2013 | 07:50AM EST
  44. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD | Nov. 20, 2013 | 12:11PM EST
  45. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 20, 2013 | 08:26AM EST
  46. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for Treatment of Patients with Morquio A Syndrome

    Benzinga | Nov. 19, 2013 | 17:04PM EST
  47. BioMarin Stock Trading Halted Today for FDA Endocrinologic and Metabolic Drugs Advisory Committee

    Benzinga | Nov. 19, 2013 | 07:11AM EST
  48. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga | Nov. 12, 2013 | 16:41PM EST
  49. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts | Nov. 7, 2013 | 12:54PM EST
  50. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer

    Benzinga | Oct. 31, 2013 | 05:58AM EST
Trading Center